Abstract
Major depressive disorder (MDD) is a common and often severe condition that profoundly diminishes quality of life for individuals across ages and demographic groups. Unfortunately, current antidepressant and psychotherapeutic treatments exhibit limited efficacy and unsatisfactory response rates in a substantial number of patients. The development of effective therapies for MDD is hindered by the insufficiently understood heterogeneity within the disorder and its elusive underlying mechanisms. To address these challenges, we present a target-oriented multimodal fusion framework that robustly predicts antidepressant response by integrating structural and functional connectivity data (sertraline: R2 = 0.31; placebo: R2 = 0.22). Through the model, we identify multimodal neuroimaging biomarkers of antidepressant response and observe that sertraline and placebo show distinct predictive patterns. We further decompose the overall predictive patterns into constitutive network constellations with generalizable structural-functional co-variation, which exhibit treatment-specific association with personality traits and behavioral/cognitive task performance. Our innovative and interpretable multimodal framework provides novel insights into the intricate neuropsychopharmacology of antidepressant treatment and paves the way for advances in precision medicine and development of more targeted antidepressant therapeutics.
Trial Registration Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression (EMBARC), NCT#01407094
Competing Interest Statement
G.A.F. received monetary compensation for consulting work for SynapseBio AI and owns equity in Alto Neuroscience. A.E. reports salary and equity from Alto Neuroscience and equity in Akili Interactive and Mindstrong Health. C.J.K reports equity from Alto Neuroscience. The remaining authors declare no competing interests.
Clinical Trial
NCT01407094
Funding Statement
This work was supported by NIH grant nos. R01MH129694, R21MH130956, R21AG080425, Alzheimer Association Grant (AARG-22-972541), and Lehigh University FIG (FIGAWD35), CORE, and Accelerator grants. Portions of this research were conducted on Lehigh University Research Computing infrastructure partially supported by NSF Award 2019035. G.A.F. was also supported by philanthropic funding and NIH grant nos. K23MH114023 and R01MH125886, and grants from the One Mind - Baszucki Brain Research Fund, the SEAL Future Foundation, and the Brain and Behavior Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The EMBARC data are publicly available through the National Institute of Mental Health Data Archive (NDA) (https://nda.nih.gov/edit_collection.html?id=2199).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes